SER — Serina Therapeutics Balance Sheet
0.000.00%
- $58.10m
- $54.30m
- $0.06m
Annual balance sheet for Serina Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.527 | 0.584 | 0.645 | 0.345 | 3.67 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.326 | 0.025 | 0.004 | 0.057 | — |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 2.28 | 2.23 | 2.45 | 0.754 | 5.68 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0 | — | — | — | 1.05 |
Net Intangible Assets | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 3.92 | 3.15 | 3.24 | 12 | 6.72 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 5.36 | 8.97 | 10.1 | 5.91 | 2.37 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 9.04 | 15 | 20.5 | 6.5 | 6.08 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -5.12 | -11.8 | -17.2 | 5.47 | 0.641 |
Total Liabilities & Shareholders' Equity | 3.92 | 3.15 | 3.24 | 12 | 6.72 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |